absolute lymphocyte count of 0.77 × 10 9 cells/L, serum creatinine level of 124.6 μmol/L (1.41 mg/dL), platelet count of 92 × 10 9 cells/L, and serum aspartate aminotransferase (AST) level of 94 U/L ( Figure 2 and Appendix Table 1 , available at www.annals.org). His serum glucose level was 10.0 mmol/L (180 mg/dL). Computed tomography scans of the head, abdomen, and pelvis without contrast were unremarkable. The patient was discharged home on illness day 3 with a prescription for azithromycin for presumed sinusitis.
The patient returned to the ED on illness day 5 with abdominal pain, diarrhea, fever, chills, headache, poor appetite, and generalized weakness. On arrival, he reported recent travel from Liberia but denied recent exposure to persons with known EVD or febrile illness in Liberia. He reported large-volume watery diarrhea occurring 6 to 8 times per day and 1 episode of nausea and vomiting 2 days earlier. His vital signs were a temperature of 39.5°C, heart rate of 107 beats/min, blood pressure of 130/81 mm Hg, and respiratory rate of 22 breaths/min. His physical examination was remarkable for mild, diffuse abdominal tenderness that was worse in the right upper quadrant. Pertinent laboratory results included leukopenia, thrombocytopenia, hyponatremia, and elevated serum glucose and AST levels (Appendix Table 1 ). Results of a malaria rapid antigen test, a stool culture, and Giardia and Cryptosporidium antigen tests were negative, and results of chest radiography and abdominal ultrasonography were normal. While in the ED, the patient had projectile vomiting and explosive diarrhea. Because EVD was suspected, the patient was kept in an ED isolation room under standard, droplet, and contact precautions, and a blood specimen was collected for EBOV testing. Two liters of normal saline were administered by bolus infusion. Levofloxacin therapy was started empirically to treat enteric bacterial infections. The patient was transferred to an ICU isolation room on illness day 6, where he reported severe myalgia and arthralgia. Fluid resuscitation continued, with 2.4 L of normal saline plus a 1.5-L bicarbonate infusion started that day.
A team of infection preventionists trained ED staff during the initial hours of care and ICU staff before ICU transfer according to then-current guidelines from the Centers for Disease Control and Prevention. Additions to personal protective equipment (PPE) included fullbody suits with head covering and powered airpurifying respirators beginning on the evening of illness day 7.
On illness day 7, abdominal pain and diarrhea (estimated at up to 10 L/d) persisted, and a rectal tube was placed for stool containment and measurement. Intravenous hydration continued, with 9.7 L of normal saline and 2.25 L of sodium bicarbonate solution in 5% dextrose in water given per 24 hours. Electrolyte replacement continued per routine ICU protocol. Levofloxacin was replaced with ertapenem. A peripherally inserted central catheter was placed for hydration and blood collection. Serum aminotransferase levels increased sharply, with a peak serum AST level of 1308 U/L. Diarrhea remained copious, up to an estimated 8 L/d. Infec-
EDITORS' NOTES Context
A cluster of Ebola virus disease (EVD) cases occurred in a hospital in Dallas, Texas.
Contribution
Detailed information is provided on the clinical course of the index case patient and 2 nurses who developed EVD after caring for him. The nurses were diagnosed early in the disease course. Management of all patients included close monitoring, full hemodynamic and other support, and use of experimental therapies. The index patient died, and the nurses survived.
Caution
The specific contribution of experimental therapies to survival could not be determined.
Implication
Survival from EVD may be improved with intensive care. Determination of additional benefits of specific therapies requires formal study.
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tion with EBOV was confirmed on illness day 7 by qRT-PCR (Ct value, 19) in the blood specimen collected on illness day 5. A blood specimen collected on illness day 6 yielded a Ct value of 17 by qRT-PCR for EBOV, reflecting high viral load. The patient's condition remained unchanged on illness day 8.
On illness day 9, the patient's fever continued. His antibiotics were changed to vancomycin, piperacillintazobactam, and levofloxacin because of concerns about possible health care-associated pneumonia and bacterial sepsis. The peak potassium supplementation was 120 mmol per 24 hours on illness day 9. Chest radiography revealed new bilateral pulmonary infiltrates consistent with pulmonary edema or pneumonia. Blood cultures were not performed because of risk to laboratory workers. A nephrology consultation diagnosed acute tubular necrosis. On illness day 10, piperacillin-tazobactam was replaced with meropenem because of worsening renal function on illness day 9 (creatinine level, 237.8 μmol/L [2.69 mg/dL]) and decreasing platelet count. Fresh frozen plasma was administered for coagulopathy on illness days 9 and 10 (maximum international normalized ratio, 2.0 [Appendix Table 1 ]), with minimal bleeding from puncture sites. Intake and output were kept matched, electrolytes were replaced per standard ICU protocol, and 25% albumin infusions were administered every 6 hours on illness days 7 to 11. High levels of supplemental oxygen were required to maintain oxygen saturation (nonrebreather mask at 15 L of O 2 per minute) on illness day 9. Chest radiography showed bilateral diffuse pulmonary infiltrates. A dose of diphenoxylate-atropine was administered for diarrhea. The patient's blood type was B, and no suitable donor for convalescent plasma therapy was available.
Discussions were held with clinical partners who had experience in managing patients with EVD in the United States and with the U.S. Food and Drug Administration (FDA) regarding the availability and potential use of investigational therapeutics, and to weigh the potential benefits and harms of such treatments in a patient with elevated aminotransferase levels and severe diarrhea. ZMapp (an experimental cocktail of 3 EBOV-specific monoclonal antibodies [Mapp Biopharmaceutical]) was unavailable. On the basis of unpublished in vitro data, an emergency Investigational New On illness day 10, the patient developed oliguria, his serum creatinine level increased to 516.3 μmol/L (5.84 mg/dL), and his fractional urinary excretion of sodium was 1.2%. Despite furosemide administration, anuria occurred. The patient was given a second dose of diphenoxylate-atropine. That night, he was sedated, medically paralyzed, and intubated for hypoxemic respiratory failure, and a hemodialysis catheter was placed. On illness day 11, his fever resolved, and continuous venovenous hemodialysis without anticoagulation was started using the NxStage system (Central Infusion Alliance). After informed consent by the patient's family and approval of an eIND request by the FDA and the hospital's institutional review board, the patient was given a 200-mg loading dose of brincidofovir via orogastric tube at 3:00 p.m. The continuous venovenous hemodialysis system clotted after 12 hours, and a citrate protocol was initiated. Stool output decreased to 1.4 L/d and then nearly stopped. Total parenteral nutrition was initiated and continued for 4 days. Later that day, the patient became hypotensive and required norepinephrine infusion.
On illness day 12, very high serum levels of AST and alanine aminotransferase (ALT) (>3600 U/L) were attributed to propofol used for sedation ( Figure 2 and Appendix Table 1 ). The patient's aminotransferase lev- ORIGINAL RESEARCH Clinical Management of 3 Patients With Ebola Virus Disease els decreased but remained elevated after propofol was withdrawn. Micafungin was added empirically to the antimicrobial therapy. Stress doses of glucocorticoids were initiated, and the patient was weaned off norepinephrine. The patient remained critically ill during illness days 12 to 14, with high oxygen requirements (Appendix Table 1 ). His total leukocyte count continued to increase (to 51 × 10 9 cells/L), and he continued to receive vancomycin, meropenem, and micafungin. Diarrhea persisted throughout the patient's hospitalization and worsened with initiation of tube feedings. A blood specimen collected on illness day 13 had detectable IgM, but IgG antibodies to EBOV were not detected (Appendix Table 1 ). On illness day 14, the patient received a second dose of brincidofovir (100 mg). On illness day 15, his temperature increased to 39.1°C, and profound hypotension developed rapidly. Treatment with vasopressors was restarted, and acidosis and hyperglycemia worsened, with his serum lactate level increasing to 19.07 mmol/L. Within 8 hours, bradycardia that did not respond to atropine developed, and pulseless electrical activity occurred. In accordance with the patient's earlier request for no chest compressions or cardioversion, no further resuscitation efforts were performed.
Patient 2
Patient 2 was a previously healthy 26-year-old woman who provided critical care nursing for the index patient on 29 and 30 September and 1, 5, and 7 October 2014 (illness days 6 to 8, 12, and 14). She denied any known exposure event occurring while she was providing direct care to the index patient and wore more than the minimum PPE recommended as of September 2014, although this initially did not include complete head and neck coverage (11). On 9 October, she had a suspected exacerbation of allergic rhinitis with nasal congestion and rhinorrhea. She had an oral temperature of 38.1°C on the night of 10 October (illness day 1) and presented to the ED at 1:00 a.m. on 11 October (Figure 1 ). She reported insomnia, slight headache, mild nasal congestion, and throat discomfort. She was placed in an ED isolation room designated for a person under investigation for EVD.
Her temperature was 38.2°C, her heart rate was 117 beats/min, and her blood pressure was 138/100 mm Hg. Her physical examination was unremarkable. Table 2 , available at www .annals.org). A plasma specimen collected that day tested positive for EBOV RNA by RT-PCR (Ct value, 32). A nasopharyngeal swab was negative for a panel of respiratory pathogens by multiplex PCR.
The patient was admitted to an isolation room in the ICU. She remained stable, with intermittent fever, headache, nausea, and vomiting. She had no diarrhea during the first 4 days of her illness. A peripherally inserted central catheter was placed for intravenous hydration and blood specimen collection. The patient developed mild thrombocytopenia and anemia. Supportive care included close monitoring of fluids and electrolytes and treatment with acetaminophen, hydrocodone, ondansetron, phenazopyridine, meperidine, morphine, diphenhydramine, pantoprazole, vitamins, electrolyte supplements, and protein-rich oral supplements. Antibiotics were not administered.
Multiple investigational therapies were administered with the patient's informed consent after approval of an eIND request by the FDA and the hospital's institutional review board (Table and Figures 1 and  3) . She received oral brincidofovir in a 200-mg loading dose on illness day 3 and a 100-mg dose on illness day 6. Two 500-mL infusions of convalescent plasma (matched by blood type) from a recovered patient with onset of EVD 81 days earlier were administered on illness days 3 and 4 and were well-tolerated. On illness day 4, elevated serum aminotransferase levels were observed ( Figure 3 and Appendix Table 2 ). The small interfering RNA molecule TKM-Ebola (Tekmira Pharmaceuticals) was administered intravenously at 0.3 mg/kg of body weight on illness day 4 after premedication with acetaminophen and diphenhydramine. Approximately 6 hours after the infusion started, the patient developed high fever (40.0°C), rigors, and chills consistent with cytokine release syndrome from TKMEbola, and acetaminophen and meperidine were administered. She also developed tachycardia and systolic hypotension for several hours that responded to a 25% albumin infusion. On illness days 5 and 6, a reduced dosage of TKM-Ebola (0.24 mg/kg) was welltolerated. On illness day 5, one 44.8-mg/kg (recommended dose, 50 mg/kg) intravenous dose of ZMapp was administered without adverse effects.
On illness day 5, before the ZMapp dose and the second TKM-Ebola dose, the patient developed a mild cough with dyspnea and was suspected to have pulmonary edema, with clinical improvement after a 20-mg intravenous dose of furosemide. A faint, diffuse morbilliform rash on the extremities and trunk was noted. On illness day 6, intermittent diarrhea occurred and an increase in serum aminotransferase levels was observed ( Figure 3) . On illness day 7, the patient was transferred to a hospital with a biocontainment patient care unit. At the time of transfer, she had been afebrile for 24 hours and had a semiformed stool. She reported increased energy and appetite and was ambulating.
On arrival at the second hospital, the patient had intermittent headaches and anorexia that persisted without fever for several days. She received 900 mL of normal saline per 24 hours (with potassium supplementation), followed by combined oral and intravenous hydration the next day and oral fluids thereafter. Given her clinical improvement, increasing Ct values (reflecting decreasing EBOV RNA levels), and unexplained increase in serum aminotransferase levels, further treatment with TKM-Ebola and brincidofovir was withheld ( Figure 3) . A blood specimen collected on illness day 8 was negative for EBOV by qRT-PCR. The patient's serum aminotransferase levels peaked on illness day 9
Clinical Management of 3 Patients With Ebola Virus Disease ORIGINAL RESEARCH and then gradually decreased ( Figure 3 and Appendix Table 2 ). Blood specimens collected for EBOV RNA testing on illness days 9 and 11 to 16 remained negative. Throat, rectal, vaginal, and urine specimens were negative for EBOV RNA on illness day 12, as were sweat samples collected from 2 different locations on illness day 14. Ebola virus-specific IgM and IgG antibodies were detected by enzyme-linked immunosorbent assay after receipt of convalescent plasma and ZMapp ( Figure 3 and Appendix Table 2 ). The patient was discharged on illness day 15. In follow-up 12 days after discharge, her only reported symptom was arthralgia managed by nonsteroidal anti-inflammatory drugs; serum AST and ALT levels were 27 and 38 U/L, respectively (Appendix Table 2 ).
Patient 3
Patient 3 was a previously healthy 29-year-old woman who provided critical care nursing for the index patient on 30 September and 1, 5, and 7 October 2014 (illness days 7, 8, 12, and 14) . She denied any known exposure event occurring while she was providing direct care to the index patient and also wore more than the minimum PPE recommended as of September 2014 (11) . Per instructions, she monitored her temperature and symptoms; other than fatigue and decreased appetite beginning on 10 October, she was asymptomatic. On 14 October, self-measured oral temperature readings were 37.9°C and 38.1°C, and she presented to the ED reporting that her eyes appeared jaundiced (Figure 1) . The patient had 2 nonbloody diarrheal stools in the ED. Her physical examination was remarkable only for a faint erythematous macular rash on her left forearm that spread to her extremities and trunk, an oral temperature of 37.9°C, tachycardia (138 beats/ Table 3 , available at www .annals.org). She was placed in an ED isolation room designated for a person under investigation for EVD. Because of the high suspicion for EVD, empirical treatment with oral brincidofovir (200 mg) was started at 6:00 p.m. in the ED after approval of an eIND request by the FDA and the hospital's institutional review board (Table) .
The patient's fever persisted, with a maximum oral temperature of 38.9°C, but her tachycardia was alleviated with intravenous fluids. Her blood pressure remained normal and her oxygen saturation remained at 99% to 100% on room air, but she continued to have watery diarrhea. A blood specimen collected on 14 October was positive for EBOV RNA by qRT-PCR (Ct value, 30). The patient was transferred to the EVD isolation unit in the ICU and was then transferred to another hospital with a biocontainment patient care unit.
On arrival at the second hospital 1 day after fever onset, the patient had mild pruritus, nausea, anorexia, and diarrhea, but intravenous hydration was not needed. Approximately 38 hours after fever onset, 600 mL of blood type-matched convalescent plasma from a recovered patient with onset of EVD 85 days earlier was administered and was well-tolerated.
The patient's diarrhea continued the next day, but her serum aminotransferase levels decreased slightly and her leukopenia resolved (Appendix Table 3 ). An additional 500-mL dose of convalescent plasma from Elevations in serum ALT/AST levels Convalescent plasma -eIND application for donated plasma 6, 7 † 600-mL IV infusion (day 6), then 500 mL (day 7)
None ALT = alanine aminotransferase; AST = aspartate aminotransferase; eIND = emergency Investigational New Drug; IV = intravenous. * Small interfering RNA molecule. † Day 1 was the day of earliest suspected illness onset (10 October 2014); fever onset was 14 October 2014.
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the same donor was administered and was welltolerated. Three days after fever onset, her diarrhea resolved and her serum AST and ALT levels continued to decrease ( Figure 4) . Polymerase chain reaction testing of stool collected that day was positive for a Campylobacter species. On the evening of the fourth day after fever onset, shortly after receiving a second dose of oral brincidofovir (100 mg), the patient experienced transient swelling and erythema of both hands and a facial rash. Five days after fever onset, the patient's serum AST and ALT levels began to increase again (Figure 4 and Appendix Table 3 ). During the next 3 days, she had multiple semiformed, steatorrheic-appearing bowel movements. Because her stool again tested positive for a Campylobacter species by PCR, the patient received oral azithromycin (500 mg) daily for 3 days. Loose stools continued for 2 more days, when she was placed on a low-fat diet, and her serum AST and ALT levels began to decrease. Thereafter, she experienced only mild fatigue and dyspnea with exertion and remained afebrile.
Testing of serial blood specimens by qRT-PCR indicated increasing Ct values over time, which reflected 
Leukocyte Count
Trends in serum aminotransferase levels, platelet count, and leukocyte count are shown in the top graph. Horizontal dotted bars denote the periods during which investigational therapeutics were administered, with individual doses indicated in solid color within those periods. Decrease in blood EBOV RNA levels (as reflected by increase in Ct values) and appearance of antibodies to EBOV (indicated as reciprocal titers) are shown in the bottom graph. ALT = alanine aminotransferase; AST = aspartate aminotransferase; Ct = cycle threshold; EBOV = Ebola virus.
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decreasing EBOV RNA levels. Ebola virus RNA was undetectable 6 days after fever onset (Figure 4) . Ebola virus-specific antibodies were first detected 3 days after fever onset and peaked 3 days later (Figure 4) . However, as in patient 2, differentiation of intrinsic humoral responses from antibodies derived from the donor's plasma was not possible. Serial urine specimens were positive for EBOV RNA by qRT-PCR until 8 days after fever onset. Vaginal and skin swab specimens collected 9 and 12 days after fever onset, respectively, were both negative for EBOV RNA. The patient was discharged home 14 days after fever onset. Her serum AST and ALT levels 7 days after discharge were 42 and 137 U/L, respectively. On day 40 after fever onset, these levels were 24 U/L and 35 U/L, respectively (Appendix Table  3 ). Trends in serum aminotransferase levels, platelet count, and leukocyte count are shown in the top graph. Horizontal dotted bars denote the periods during which investigational therapeutics were administered, with individual doses indicated in solid color within those periods. Decrease in blood EBOV RNA levels (as reflected by increase in Ct values) and appearance of antibodies to EBOV (indicated as reciprocal titers) are shown in the bottom graph. Suspected illness onset date was 10 October 2014; fever onset date was 14 October 2014. ALT = alanine aminotransferase; AST = aspartate aminotransferase; Ct = cycle threshold; EBOV = Ebola virus.
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DISCUSSION
This cluster of EVD cases included the first domestically acquired EBOV infections in 2 critical care nurses who provided direct care to the first patient diagnosed with EVD in the United States. Despite aggressive supportive critical care, including invasive mechanical ventilation, vasopressors, and continuous renal replacement therapy, the index patient died. He received 2 doses of an investigational treatment (brincidofovir) on illness days 11 and 14, relatively late in his clinical course. Immunoglobulin M antibodies were detectable by illness day 6, although IgG was never detected. The index patient was older than the other patients and his Ct values reflected a high blood EBOV viral load-both poor prognostic indicators-and undiagnosed diabetes may also have contributed to his death. In addition, the history obtained from him may not have been accurate regarding onset of illness and exposure. The patient and his family denied EBOV exposure in discussions with multiple examiners and health department officials. Any reports of known exposure were obtained outside this hospital or the local health department. The secondary patients were young adults without comorbid conditions, and neither had substantial gastrointestinal fluid losses or severe complications compared with other patients with EVD, including the index patient (2, 3, (12) (13) (14) . Although the source and timing of transmission are unknown, the similarities of their clinical courses and virologic data suggest that both might have acquired EBOV infection during a similar period.
Patients 2 and 3 developed mild nonspecific symptoms and mildly elevated temperature before diagnosis of EVD. This suggests that the earliest signs and symptoms of EBOV infection may be mild, subtle, and nonspecific before fever onset, a finding that has implications for surveillance of persons with known exposure to a patient with EVD. Similarly, malaise and lowgrade fever for 3 days before temperature elevation to greater than 38°C were described in a Spanish patient with EVD (15) . For patient 2, the possible incubation period between the last and earliest known exposures to the index patient and fever onset was 3 to 12 days.
Although the timing of illness onset in patient 3 is uncertain, the clinical (rash) and laboratory (leukopenia, lymphopenia, and thrombocytopenia) findings at fever onset and presentation were consistent with illness onset approximately 4 to 5 days earlier, based on the natural history of EVD (16) . An alternative explanation for these findings is possible incipient Campylobacter enteric infection, although this was based on a positive stool PCR result without stool culture. Patient 3 had a possible incubation period of 3 to 15 days after exposure to the index patient and illness onset during 10 to 14 October 2014.
Both surviving patients received multiple investigational therapies, including convalescent plasma. Testing of blood specimens indicated moderately high Ct values by qRT-PCR, which reflected low to moderate EBOV RNA levels in both patients, with clearance of viremia correlating with resolution of clinical illness.
However, the clinical benefit and relative effect of the investigational therapies on clearance of viremia are unknown because different treatments overlapped with each other and were uncontrolled. Use of these experimental therapies is supported only by uncontrolled observational findings in patients with EVD, in vitro data, and preclinical safety data from healthy volunteers or studies of use of these therapies in other viral illnesses. Given the moderate degree of illness in these patients and their low EBOV RNA levels, it is possible that both would have recovered with supportive care alone.
We were unable to attribute the observed elevations in serum aminotransferase levels after clinical improvement in both surviving patients to a specific agent or intervention. The observed patterns of ALT elevation that were similar to or higher than those for AST suggested potential drug toxicity rather than EBOV infection, which typically manifests as a marked elevation in serum AST levels compared with ALT levels (2, (12) (13) (14) . Serum ALT elevation has been reported with brincidofovir treatment (17) . In patient 2, this uncertainty about potential drug toxicity influenced the decision to withdraw 2 experimental agents.
This experience provides evidence that survival of patients with EVD can be improved by timely provision of full hemodynamic support, including aggressive fluid replacement, and diagnosis and correction of metabolic derangements (2, 3, 12-14, 16 -19) . It also highlights a need for controlled clinical trials of investigational therapies, including convalescent plasma. Such trials need to be conducted among patients with EVD in low-resource settings in western Africa and in facilities in developed countries. 
